Essex Bio-Technology Signs Exclusive Distribution Deal with Osteopore Worth Over RMB12 Million

Reuters01-15
<a href="https://laohu8.com/S/01061">Essex Bio-Tech</a>nology Signs Exclusive Distribution Deal with <a href="https://laohu8.com/S/OSX.AU">Osteopore</a> Worth Over RMB12 Million

Essex Bio-Technology Limited announced that its wholly-owned subsidiary, Majeton Pte Ltd, has entered into an exclusive distribution agreement with Osteopore International Pte Ltd. Under the agreement, Majeton will act as the exclusive distributor of Osteopore’s dental, orthodontic, and maxillofacial products in the People’s Republic of China, Hong Kong, and Macau. The agreement has an expected contract value exceeding RMB12 million, including upfront and milestone payments, with potential for additional purchases and supply of products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Essex Bio-Technology Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260115-11992120), on January 15, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment